For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Subvariant reinfection in Kiwi teens - New Zealand family a case study in the As and Bs of Omicron
+Print Archive
News
Subvariant reinfection in Kiwi teens - New Zealand family a case study in the As and Bs of Omicron
Wednesday 16 March 2022, 02:55 AM

Siblings Rupert and Scarlett Giffin tested COVID-19-positive twice in two months [Supplied]
Key points, Teenage siblings testing positive for COVID-19 twice in two months may be a case of Omicron reinfection by subvariant BA.2.
Genomic surveillance fou, BACK panel - grey
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
1. Stegger M, Edslev SM, Sieber RN et al. Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection. medRxiv 2022.02.19.22271112.
2. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 36. UK Health Security Agency, 11 February 2022.